The EMA will assess the marketing authorisation for the medication to see whether it is a cause of skin cancer in patients.
The post EMA to review Picato after rise in skin cancer cases appeared first on European Pharmaceutical Review.
Original Article: EMA to review Picato after rise in skin cancer cases